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Abbreviation
DKA Diabetic ketoacidosis
On the 31 December 2014, 13-year-old Peter Baldwin from
Cardiff, UK, was taken to his GP with symptoms of a wors-
ening chest infection, thirst and tiredness. His blood glucose
was not checked, new-onset type 1 diabetes was missed, and
Peter subsequently went on to develop severe diabetic
ketoacidosis (DKA). Despite the best efforts of paramedics
and healthcare staff, Peter unfortunately did not get past the
first few days of his type 1 diabetes and passed away soon
after. A tragic loss to all that knew him, and of a promising
young life [1].
Unacceptably high proportions of children are diagnosed in
DKA (24% in England and Wales, 30% in the US state of
Colorado [2, 3]). In this issue of Diabetologia, Lundgren
and colleagues report the results of a study that extends our
understanding of some of the benefits of screening and allows
us to explore more proactive approaches to diagnosing type 1
diabetes [4].
Detectable evidence of beta cell immunity precedes the
clinical presentation of type 1 diabetes by a number of years
[5]. This immunity is most efficiently measured by a blood
test for autoantibodies to beta cell-associated proteins such as
GAD, insulin and islet antigen 2 (IA2) [6]. Combined with the
use of genetic markers [7] and oral glucose challenge, these
tests allow detection of people at risk of developing type 1
diabetes long before the onset of hyperglycaemia and of
symptoms [8]. Currently, these investigations are used for re-
search purposes, to understand the natural history and devel-
opment of type 1 diabetes, and to identify individuals in whom
prevention therapies can be tested.
However, cases like those of Peter Baldwin, and the signif-
icant proportion of children who present with DKA at diag-
nosis, make us question whether these screening tests should
be rolled out to the general population. This is an emotive
topic and one we should explore carefully. The current think-
ing on this subject suggests we should not be routinely screen-
ing for type 1 diabetes because there is no therapy currently
proven to prevent or significantly delay the onset of this con-
dition. This is supported by guidelines from respected author-
ities in this area [9]. However, this does not consider the ben-
efits associated with early detection of type 1 diabetes, not
least of which is prevention of death by DKA.
So, what are the benefits of screening for type 1 diabetes?
A number of research studies have now outlined what these
may be (Table 1). These research studies have either screened
the general population or been more focused and screened
people deemed at risk because they have a family member
with the disease. Screening has been undertaken through ge-
netic and autoantibody tests followed by glucose tolerance
tests for those deemed at risk. To date, screening studies have
largely studied children and not explored adults (the age group
in which almost 40% of type 1 diabetes presents). The benefit
most consistently reported across these studies is avoidance of
DKA. This is a significant benefit, with a reduction from a
quarter of new type 1 diabetes being diagnosed in DKA down
to 3%. Also, presumably because they are diagnosed at an
earlier stage of disease, there is more residual beta cell func-
tion (as measured by C-peptide), lower insulin requirements
and lower HbA1c at the time of diagnosis [10–15]. The paper
by Lundgren and colleagues [4] adds to the evidence. They
report from follow-up of the Diabetes Prediction in Skane
(DiPiS) study, where almost 40,000 children in southern
Sweden were screened for type 1 diabetes. Of these, 6000
were deemed to be at some degree of risk and offered
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Table 1 Benefits associated with screen-detected type 1 diabetes
Study Age group Less DKA Lower HbA1c Lower insulin dose Shorter period
in hospital
Others
BabyDiab and Munich Family study [27] Paediatric Y Y N Y
DiPiS [10, 11] Paediatric Y Y N ND
TEDDY [13] Paediatric Y Y Y ND Higher residual C-peptide
DAISY [12] Paediatric Y Y Y Y
DIPP [14, 15] Paediatric Y Y ND ND Less weight loss
DAISY, Diabetes Autoimmunity Study in the Young
DiPiS, Diabetes Prediction in Skane
DIPP, Finnish Type 1 diabetes Prediction and Prevention
ND, not determined
TEDDY, The Environmental Determinants of Diabetes in the Young
Table 2 Screening for type 1 di-
abetes set against WHO criteria
for screening [19]
Criterion Satisfied
The condition sought should be an important
health problem
Yes
Type 1 diabetes is an important health problem. Whilst
early screening does not currently allow us to institute
preventative therapy, it may prevent comorbidity
associated with late presentation
There should be an accepted treatment for
patients with recognised disease
Yes
People at risk will be provided with education until they
are formally diagnosed with diabetes, at which time they
will be initiated on insulin. Early education and initiation
of insulin are likely to be acceptable and effective
Facilities for diagnosis and treatment should
be available
Yes
Most healthcare facilities have access to phlebotomy and
oral glucose challenge facilities. Samples can be sent to
reference centres nationally for analysis
There should be a recognisable latent or early
symptomatic stage
Yes
Latent and early symptomatic phase can be detected through
autoantibody and glucose challenge
There should be a suitable test or examination Yes
Peripheral blood tests for antibodies and oral glucose
challenge
The test should be acceptable to the population Not known
The psychological consequences of awareness of high risk
of a chronic disease for which there is no cure is not known
The natural history of the condition, including
development from latent to declared
disease, should be adequately understood.
Not known
Natural history remains to be fully elucidated, different rates
of progression remain to be understood. Age, ethnicity and
environment appear to influence natural history and
these effects remain to be elucidated
There should be an agreed policy on whom to
treat as patients
Yes
People fulfilling standard WHO criteria for diabetes will be
treated as diabetic
The cost of case-finding should be
economically balanced in relation to
possible expenditure on medical care
as a whole
Not known
Case-finding should be a continuing process
and not a ‘once and for all’ project
Yes
A long-term programme can be implemented nationally
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follow-up. About two-thirds accepted this offer of follow-up.
Lundgren and colleagues report on the outcome of the 51
children who developed type 1 diabetes in the follow-up
group, compared with the 78 who developed type 1 diabetes
but had not accepted the offer of follow-up. Children who
chose follow-up had a lower frequency of DKA (2% vs
18%), and lower HbA1c (9 mmol/mol [0.8%] lower) at diag-
nosis. Importantly, HbA1c remained significantly better up to
5 years after diabetes diagnosis. A potential caveat is that a
greater proportion of the participants who opted for follow-up
had mothers of Swedish origin, and a greater engagement in
research may reflect a propensity for greater involvement in
diabetes care following diagnosis. That said, this is the first
time that such a prolonged HbA1c benefit has been reported,
and this HbA1c benefit has a clear clinical and economic ben-
efit. Furthermore, since HbA1c generally tends to rise in the
first years after diagnosis, and then stabilise and ‘track’ after
about 5 years [16], we could postulate that the lower HbA1c
levels in the follow-up group persist over the long term.
Do these benefits make a workable case for screening?
There are those who would put forward a scientific argument
to support this case [17, 18]. To provide some clarity, Table 2
presents the benefits of screening against the WHO guidelines
for screening, originally proposed almost 50 years ago [19].
Here, the benefits relate to early detection, and not to preven-
tion of the disease. There are a number of criteria that remain
to be satisfied.
First, we do not know the psychological consequences of
alerting a person to a condition for which there is no current
cure. Granted, this time may usefully be spent in educating
and preparing the person for managing type 1 diabetes.
However, concurrent work on the psychological impact of
informing patients of high risk of type 2 diabetes suggests that,
even with a condition that can be significantly delayed, there
can be a negative psychological impact. These include nega-
tive markers of mental health, reduced motivation and lack of
engagement with behaviour change [20].
Second, the natural history of type 1 diabetes is still not clear-
ly understood, and the influence of age, ethnicity and environ-
ment remain to be elucidated. The environment may influence
the rate of development, as evidenced by migration studies,
where populations migrating from areas of low incidence to high
appear to adopt the risk of the host population [21]. Whilst we
previously believed that rates of beta cell loss were faster at a
younger age, more recent work suggests that the ratemay remain
the same across the age spectrum [22], despite islet histology
changing with age of presentation [23]. Importantly, all major
screening studies to date have focused on children.
Lastly, the cost benefit needs to be established for a formal
screening programme. Since 2015 the Bavarian Fr1da study
has been screening children aged 3–4 years for type 1 diabetes
[24]. The aim is to screen 200,000 children, with each screen-
ing roughly costing 20 Euros per child. If DKA and
hospitalisation is prevented in 200 children, this cost saving
will in itself cover a third of the cost of the study. Furthermore,
patients presenting with DKA tend to have anHbA1c that is up
to 1.4% higher than those who do not over the long term [3]. If
the lower HbA1c reported by Lundgren et al persists to reduce
the incidence and economic impact of diabetic complications,
combined with the saving on DKA cost, we may be a signif-
icant way to covering the economic cost of screening. Further
work is required in this area.
Until some of the issues above are resolved (and there is
significant work ongoing) the way forward is in public and
healthcare education, and raising awareness. As a direct result
of the efforts of Peter Baldwin’s family, theWelsh government
recently (October 2018) discussed ten recommendations
around raising awareness of type 1 diabetes. These recom-
mendations include adopting the Diabetes UK 4Ts campaign
[25], and a recommendation that all cases diagnosed in DKA
are reviewed for shared learning [26]. These measures are
critical if we are going to make a meaningful change to the
devastation caused by death by DKA.
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